What are the latest funding news in the femtech market? (October 2026)
Building a startup or looking for your next investment in femtech? Our report gives you the full picture.
Femtech funding in 2026 is increasingly moving toward clinically focused products, with diagnostics, medical devices and reproductive care representing a large share of the latest deals.
The 12 most recent qualifying financings in this screen represent roughly $124 million in disclosed capital across companies ranging from pre-commercial startups to established growth-stage businesses.
Recent activity also shows that investors are backing both consumer-facing women's health companies and technologies designed to fit directly into clinical care pathways.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
Insights
- The 12 latest femtech funding deals represent roughly $124 million in disclosed financing, showing that women's health can now attract meaningful capital across diagnostics, medical devices, fertility care and clinical infrastructure.
- Seven of the 12 companies raised seed or pre-seed capital, suggesting that investors are still actively financing new femtech platforms rather than concentrating only on established women's health businesses.
- Half of the companies are primarily diagnostics or medical-device businesses, including Evvy, Aitiologic, iPremom, Freyya, Induvita and Channel Medsystems, a notable shift away from app-led femtech models.
- Evvy and Channel Medsystems alone account for $70 million, or more than half of the disclosed capital in this group, showing how funding becomes concentrated once clinical validation and commercial traction appear.
- Six of the 12 companies remain pre-commercial, pre-launch, clinical-validation or preclinical businesses, which shows that femtech investors are still willing to finance substantial scientific and regulatory risk.
- Pregnancy and fertility remain major femtech funding categories, with Bird&Be, Aitiologic, iPremom, Daré Bioscience and The American Baby Company directly addressing reproductive or maternal health.
- Two of the 12 financings are non-dilutive grants rather than equity rounds, providing about $2.2 million for women's health R&D at Daré Bioscience and Opal Therapeutics.
- The U.S. features as a primary commercial or research market for at least eight companies in this list, while European startups are particularly visible in maternal diagnostics, gynecology and menstrual health.
- September produced seven of the 12 latest qualifying femtech deals, making it an unusually active month across pelvic health, menopause care, fertility, vaginal health, maternal diagnostics and gynecological devices.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
In our report covering the femtech market, you will always find fresh funding data, taken straight from our own verified funding database.
Summary table of the latest funding deals in the femtech market as of October 2026
We define the femtech market as technology-enabled products and services that address women’s reproductive and other female-specific health needs.
We include solutions focused on menstrual and cycle health, fertility and contraception, pregnancy and postpartum, menopause, pelvic and sexual health, and clinically oriented tools for conditions that predominantly or uniquely affect women, such as breast and gynecological cancers.
We exclude general-purpose health, wellness, fitness, mental health, and consumer apps that are not specifically designed around women’s biology, care pathways, or life stages.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Freyya | 29 Sep 2026 | >$1.0M | Pre-seed | Pelvic Health & Medical Devices |
| Blair Health | 22 Sep 2026 | ~$3.0M | Pre-seed | Menopause & Women's Care Infrastructure |
| Bird&Be | 22 Sep 2026 | $13.0M | Series A | Fertility & Reproductive Health |
| Evvy | 15 Sep 2026 | $40.0M | Series B | Vaginal Health & Diagnostics |
| Aitiologic | 15 Sep 2026 | $7.4M | Seed | Pregnancy & Maternal Diagnostics |
| Induvita | 15 Sep 2026 | ~$0.75M | Seed | Gynecology & Obstetrics Devices |
| iPremom | 2 Sep 2026 | ~$17-18M | Seed | Pregnancy & Maternal-Fetal Diagnostics |
| Daré Bioscience | 31 Aug 2026 | $0.908M | NIH Grant | Pregnancy & Reproductive Therapeutics |
| Channel Medsystems | 20 Aug 2026 | $30.0M | Series C | Menstrual Health & Gynecological Devices |
| Opal Therapeutics | 6 Aug 2026 | $1.25M | NSF SBIR Phase II | Uterine Health & R&D Infrastructure |
| DITTO | 28 Jul 2026 | $6.0M | Seed | Menstrual Health & Consumer Therapeutics |
| The American Baby Company | 23 Jul 2026 | $4.0M | Seed | Fertility & Assisted Reproduction |
All the latest funding deals in the femtech market as of October 2026
Freyya raised more than $1 million in late September to advance its pelvic-floor wearable.
When was it?
Freyya announced the oversubscribed financing on September 29, 2026.
Who are they?
Freyya is developing an intravaginal wearable that measures pelvic-floor function and provides biofeedback during pelvic-floor rehabilitation.
Geographical focus?
Freyya is initially targeting the U.S. market while also preparing for future European commercialization.
Why do we include them in the femtech market?
Freyya directly addresses female pelvic-floor dysfunction, placing the company in pelvic health, medical devices and digitally supported rehabilitation.
What is the company stage?
Freyya is pre-commercial and regulatory-stage, with product development and clinical testing completed but regulatory clearance still required.
How much did they raise?
Freyya raised more than $1.0M in this financing.
What round is it?
Freyya closed an oversubscribed pre-seed round led by Alamo Angels.
Why did they raise?
Freyya raised the capital to fund its FDA submission, regulatory work, commercial-scale manufacturing preparation and future market launch.
In our research about women's health technology, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.
Blair Health raised about $3 million in September to expand specialist-designed women's healthcare.
When was it?
Blair Health announced the financing on September 22, 2026.
Who are they?
Blair Health turns specialist-designed women's health protocols into clinical software that generalist healthcare providers can use to deliver more specialized care.
Geographical focus?
Blair Health operates across Canada and is expanding into the U.S. through employers and healthcare providers.
Why do we include them in the femtech market?
Blair Health was built around menopause, pelvic health and related women's care pathways, placing it in virtual women's care and clinical infrastructure.
What is the company stage?
Blair Health is early commercial and building product-market fit, with thousands of users and early enterprise deployments already established.
How much did they raise?
Blair Health raised C$4.24M, equivalent to approximately $3.0M.
What round is it?
Blair Health's financing was its first institutional pre-seed round.
Why did they raise?
Blair Health raised the capital to develop its product, expand clinical operations and grow commercially across Canada and the U.S.
Bird&Be raised $13 million in September to expand access to fertility and reproductive care.
When was it?
Bird&Be announced the financing on September 22, 2026.
Who are they?
Bird&Be sells doctor-formulated fertility and prenatal products alongside at-home reproductive-health tests for ovarian reserve and fertility factors.
Geographical focus?
Bird&Be was founded in Canada and serves the broader North American market, with significant expansion activity in the U.S.
Why do we include them in the femtech market?
Bird&Be is centered on fertility, preconception, pregnancy and reproductive health, placing the business in fertility testing and consumer reproductive care.
What is the company stage?
Bird&Be is at the growth stage, with established direct-to-consumer sales and broad retail distribution.
How much did they raise?
Bird&Be raised $13.0M in the financing.
What round is it?
Bird&Be's financing was reported as a Series A.
Why did they raise?
Bird&Be raised the capital to accelerate product development, expand retail and clinical distribution and improve access to fertility products outside specialist clinics.
Evvy raised $40 million in September to expand its vaginal-health diagnostics and research platform.
When was it?
Evvy announced the Series B on September 15, 2026.
Who are they?
Evvy combines at-home vaginal-microbiome sequencing with clinician-reviewed results, personalized care and a large women's health biological dataset.
Geographical focus?
Evvy is primarily focused on the U.S. consumer, clinical and research markets.
Why do we include them in the femtech market?
Evvy's core technology focuses on vaginal biology and female-specific conditions, placing it in vaginal health, precision diagnostics and fertility research.
What is the company stage?
Evvy is a growth-stage company with strong commercial traction, a large patient base and established relationships with healthcare practitioners.
How much did they raise?
Evvy raised $40.0M in this round.
What round is it?
Evvy closed an oversubscribed Series B led by Catalio Capital Management.
Why did they raise?
Evvy raised the capital to validate new diagnostic models, expand fertility research and increase distribution through physicians and partners.
Your time is limited. In our market report about women's health technology, we put numbers on each part of the market, so you can see where it makes sense to focus.
Aitiologic raised about $7.4 million in September to advance its preeclampsia blood test.
When was it?
Aitiologic announced the seed financing on September 15, 2026.
Who are they?
Aitiologic is developing an AI-enabled blood-test platform that analyzes cell-free DNA to identify preeclampsia risk during the first trimester.
Geographical focus?
Aitiologic is based in Vienna and is developing its technology for European and ultimately international clinical markets.
Why do we include them in the femtech market?
Aitiologic's lead program addresses a major pregnancy complication, placing the company in maternal health, pregnancy diagnostics and precision medicine.
What is the company stage?
Aitiologic is at the clinical-validation and regulated-development stage, with its lead diagnostic not yet commercially approved.
How much did they raise?
Aitiologic raised €6.4M, equivalent to approximately $7.4M.
What round is it?
Aitiologic closed an oversubscribed seed round co-led by Heal Capital and Ananda Impact Ventures.
Why did they raise?
Aitiologic raised the capital to support large-scale clinical validation and regulated product development for its first-trimester preeclampsia test.
Induvita raised about $0.75 million in September to commercialize new gynecological devices.
When was it?
Induvita's financing was reported on September 15, 2026.
Who are they?
Induvita develops redesigned gynecology and obstetrics products including the Vega vaginal speculum, clinical training simulators and the Iola labor-induction catheter.
Geographical focus?
Induvita is based in Norway, already sells internationally and is preparing a broader European commercial rollout.
Why do we include them in the femtech market?
Induvita builds medical devices specifically for gynecological examinations and childbirth, placing the company in gynecology and obstetrics technology.
What is the company stage?
Induvita is early commercial, with training products generating revenue while newer medical devices move through commercialization and development.
How much did they raise?
Induvita raised NOK7.5M, equivalent to roughly $0.75M.
What round is it?
Induvita completed an early-stage equity financing with new and existing shareholders.
Why did they raise?
Induvita raised the capital to launch its Vega speculum in Europe and continue developing its Iola labor-induction catheter.
iPremom raised roughly $17 to $18 million in September to advance early pregnancy diagnostics.
When was it?
iPremom announced the financing on September 2, 2026.
Who are they?
iPremom develops molecular blood tests designed to identify the risk of major pregnancy complications from the first trimester.
Geographical focus?
iPremom is based in Valencia, Spain, and is developing its diagnostics for an international maternal-health market.
Why do we include them in the femtech market?
iPremom directly addresses pregnancy complications affecting maternal and fetal health, placing the company in pregnancy and maternal-fetal diagnostics.
What is the company stage?
iPremom is at the clinical-validation and early commercialization stage as it advances the MaiRa diagnostic platform.
How much did they raise?
iPremom raised €15M, equivalent to approximately $17M to $18M.
What round is it?
iPremom completed a seed round led by Amadeus Capital Partners with participation from Asabys Partners and APEX Ventures.
Why did they raise?
iPremom raised the capital to validate MaiRa clinically and move the pregnancy-risk testing platform toward broader commercial rollout.
In our document detailing everything you need to know about femtech, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.
Daré Bioscience received a $0.908 million NIH award in August for its preterm-birth program.
When was it?
Daré Bioscience announced the NIH award on August 31, 2026.
Who are they?
Daré Bioscience develops women's health therapeutics spanning contraception, vaginal health, sexual health, fertility, pregnancy and menopause.
Geographical focus?
Daré Bioscience is U.S.-based and develops products primarily through U.S. clinical and regulatory pathways.
Why do we include them in the femtech market?
Daré Bioscience focuses exclusively on women's health, while the funded DARE-PTB2 program specifically targets prevention of idiopathic preterm birth.
What is the company stage?
Daré Bioscience has commercial-stage activities, but the DARE-PTB2 program funded by this award remains preclinical.
How much did they raise?
Daré Bioscience received approximately $0.908M in initial funding through the award.
What round is it?
Daré Bioscience received a non-dilutive NIH and NICHD grant rather than a venture equity round.
Why did they raise?
Daré Bioscience received the funding for pharmacokinetic, safety, toxicology and other preclinical work required to advance DARE-PTB2.
Channel Medsystems reached $30 million in Series C funding in August to expand Cerene.
When was it?
Channel Medsystems announced the Series C milestone on August 20, 2026.
Who are they?
Channel Medsystems makes Cerene, an FDA-cleared cryotherapy device for treating heavy menstrual bleeding and dysmenorrhea without hormones.
Geographical focus?
Channel Medsystems is focused on commercial expansion across the U.S. gynecology market.
Why do we include them in the femtech market?
Channel Medsystems directly treats female-specific menstrual and uterine conditions, placing Cerene in menstrual health and gynecological medical devices.
What is the company stage?
Channel Medsystems is at the commercial-growth stage following the U.S. relaunch of the Cerene platform.
How much did they raise?
Channel Medsystems' ongoing Series C reached $30.0M.
What round is it?
Channel Medsystems' financing is an ongoing Series C led by InnovaHealth Partners.
Why did they raise?
Channel Medsystems raised the capital to expand its commercial organization, increase awareness, support professional training and broaden access to Cerene.
Opal Therapeutics secured $1.25 million in August to scale its uterine-organoid research platform.
When was it?
Opal Therapeutics announced the funding on August 6, 2026.
Who are they?
Opal Therapeutics creates patient-derived uterine organoids from menstrual-blood cells to support research and drug testing for female reproductive diseases.
Geographical focus?
Opal Therapeutics is U.S.-based and primarily targets pharmaceutical, biotechnology and women's health research organizations.
Why do we include them in the femtech market?
Opal Therapeutics focuses specifically on uterine biology and disorders such as endometriosis and fibroids, placing it in women's health research infrastructure.
What is the company stage?
Opal Therapeutics is pre-commercial and focused on building and validating its reproductive-health research platform.
How much did they raise?
Opal Therapeutics secured $1.25M through the award.
What round is it?
Opal Therapeutics received a non-dilutive NSF SBIR Phase II award rather than an equity financing.
Why did they raise?
Opal Therapeutics received the funding to scale its uterine-organoid samples, laboratory infrastructure and drug-screening capabilities.
Our report covering the femtech market gets updated several times a month, so you always get the latest view of where things stand.
DITTO raised $6 million in July to expand its menstrual-health research and product platform.
When was it?
DITTO announced the seed financing on July 28, 2026.
Who are they?
DITTO combines menstrual-health research with science-led supplements designed around cycle symptoms including PMS and PMDD.
Geographical focus?
DITTO is based in the UK and initially targets the UK and European consumer markets, with potential for broader international distribution.
Why do we include them in the femtech market?
DITTO's products and research are designed specifically around menstrual-cycle conditions, placing the business in menstrual health and consumer therapeutics.
What is the company stage?
DITTO is early commercial and moving into growth, with products already sold and a larger clinical research program under development.
How much did they raise?
DITTO raised $6.0M in the financing.
What round is it?
DITTO completed a seed round led by FoodLabs with participation from returning investor Eka Ventures.
Why did they raise?
DITTO raised the capital to expand its research program, run larger studies, broaden its product range and increase distribution.
The American Baby Company raised $4 million in July to launch its lower-cost fertility clinic model.
When was it?
The American Baby Company announced the seed financing on July 23, 2026.
Who are they?
The American Baby Company is building standardized fertility clinics offering services such as IVF and egg freezing at transparent, lower prices.
Geographical focus?
The American Baby Company is focused on the U.S., beginning with its first clinic in West Palm Beach, Florida.
Why do we include them in the femtech market?
The American Baby Company's core services are IVF, egg freezing and reproductive endocrinology, placing it in fertility and assisted reproduction.
What is the company stage?
The American Baby Company is at the initial commercial rollout stage, beginning with the launch of its first fertility clinic.
How much did they raise?
The American Baby Company raised $4.0M in the financing.
What round is it?
The American Baby Company completed a seed round led by Wormhole Capital and Tower Research Ventures.
Why did they raise?
The American Baby Company raised the capital to build its first clinic, establish IVF laboratory operations and prepare for a broader clinic network.
In our research about women's health technology, we look at what the winners do differently, so you can learn from the best instead of guessing.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us